Preferred Label : PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701;
NCIt synonyms : CaspaCID-based PRAME-TCR Allogeneic T-lymphocytes BPX-701;
NCIt definition : Human allogeneic T-lymphocytes transduced with a retroviral vector encoding a high-affinity
T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A2-01-restricted,
preferentially-expressed antigen in melanoma (PRAME) and containing the chemical induction
of dimerization (CID) suicide/safety switch, composed of a drug binding domain coupled
to the signaling domain of the suicide enzyme caspase-9, with potential antineoplastic
activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient,
transduced with an anti-PRAME-HLA-A2 restricted TCR, expanded ex vivo, and reintroduced
into the HLA-A2-positive patient. Upon reintroduction, PRAME-targeting T-cell receptor-based
therapy BPX-701 binds to tumor cells expressing PRAME, which may induce cell death
in and halt the growth of PRAME-expressing cancer cells. The tumor-associated antigen
PRAME is overexpressed by a variety of cancer cell types. If potential T-cell toxicity
due to graft-versus-host disease (GvHD) occurs, the chemical dimerizer rimiducid (AP1903)
can be adminstered. Rimiducid binds to the drug binding domain expressed by the BPX-701
T-cells, and triggers activation of the caspase-9 domain, which leads to caspase 9-mediated
signaling, the induction of apoptosis and to selective and complete elimination of
BPX-701 cells.;
Molecule name : BPX-701;
NCI Metathesaurus CUI : CL507923;
Origin ID : C128029;
UMLS CUI : C4287777;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
